AVT34 (durvalumab biosimilar) / Alvotech, Lotus Pharmaceutical - LARVOL DELTA

Alvotech…announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical…covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi (durvalumab), and AVT87, a proposed biosimilar to Hemlibra (emicizumab). (GlobeNewswire) - "Under a semi-exclusive agreement in the United States, Alvotech retains the right to commercialize both products directly alongside Lotus, while Lotus will commercialize the products through Alvogen, its U.S.-based wholly owned subsidiary. Alvotech will retain responsibility for product development, and for obtaining and maintaining marketing authorizations in the United States, and will serve as the exclusive supplier of the products for all markets...In Asia, Lotus will have exclusive commercialization rights in eight selected markets: South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong and Malaysia. Lotus will be responsible for local regulatory submissions and commercialization in these markets....The agreement has a potential value to Alvotech of up to approximately $150 million in upfront and milestone payments, in addition to ongoing revenues from the supply of commercial product."

Licensing / partnership • Biliary Tract Cancer • Bladder Cancer • Endometrial Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Hemophilia A • Hepatocellular Cancer • Non Small Cell Lung Cancer • Small Cell Lung Cancer • Urothelial Cancer